Work

Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study

Year: 2021
Type: article
Study design: Observational Study
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: bronze
OpenAlex ID: W3137624933
FWCI: 2.301
Cites: 39
Cited by: 33
Related to: 10